- Home
- MRM vs APM Comparison
MRM vs APM Comparison
Compare MRM & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRM
- APM
- Stock Information
- Founded
- MRM 2000
- APM 2010
- Country
- MRM Japan
- APM United Kingdom
- Employees
- MRM N/A
- APM N/A
- Industry
- MRM Other Consumer Services
- APM Biotechnology: Pharmaceutical Preparations
- Sector
- MRM Consumer Discretionary
- APM Health Care
- Exchange
- MRM Nasdaq
- APM Nasdaq
- Market Cap
- MRM 16.0M
- APM 18.9M
- IPO Year
- MRM 2020
- APM 2018
- Fundamental
- Price
- MRM $2.15
- APM $1.46
- Analyst Decision
- MRM
- APM
- Analyst Count
- MRM 0
- APM 0
- Target Price
- MRM N/A
- APM N/A
- AVG Volume (30 Days)
- MRM 2.1M
- APM 281.2K
- Earning Date
- MRM 05-22-2026
- APM 12-19-2025
- Dividend Yield
- MRM N/A
- APM N/A
- EPS Growth
- MRM N/A
- APM N/A
- EPS
- MRM 0.04
- APM N/A
- Revenue
- MRM $55,915,220.00
- APM N/A
- Revenue This Year
- MRM N/A
- APM N/A
- Revenue Next Year
- MRM N/A
- APM N/A
- P/E Ratio
- MRM $61.67
- APM N/A
- Revenue Growth
- MRM 12.79
- APM N/A
- 52 Week Low
- MRM $0.34
- APM $0.46
- 52 Week High
- MRM $4.45
- APM $7.49
- Technical
- Relative Strength Index (RSI)
- MRM 48.12
- APM 39.84
- Support Level
- MRM $2.07
- APM $1.45
- Resistance Level
- MRM $2.73
- APM $1.59
- Average True Range (ATR)
- MRM 0.21
- APM 0.11
- MACD
- MRM -0.04
- APM -0.02
- Stochastic Oscillator
- MRM 22.07
- APM 16.67
About MRM MEDIROM Healthcare Technologies Inc.
MEDIROM Healthcare Technologies Inc provides health services. The company is a franchiser and operator of healthcare salons and operates in segments namely Relaxation Salon, Digital Preventative Healthcare, and Luxury Beauty Segment. The company generates a majority of its revenue from the Relaxation Salon business segment. Geographically, the company generates a maximum share of its revenue from Japan.
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.